Oryzon Genomics S.A. (BME:ORY)

Market Cap	191.87M
Revenue (ttm)	14.19M
Net Income (ttm)	-4.08M
Shares Out	64.71M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	136.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,856,415
Average Volume	753,033
Open	2.480
Previous Close	2.395
Day's Range	2.360 - 2.965
52-Week Range	1.400 - 2.965
Beta	0.69
RSI	95.20
Earnings Date	Feb 26, 2025

About Oryzon Genomics

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical developme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 46
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ORY

Financial Performance

In 2023, Oryzon Genomics's revenue was $14.19 million, a decrease of -9.60% compared to the previous year's $15.70 million. Losses were -$3.35 million, -20.76% less than in 2022.

Financial numbers in USD